#### AGGREGATE REPORT

Title: Test 2

**Facility: NewHealth Center** 

Duration:From: 2021-07-01 To 2021-12-31

### **DSTB**

Proportion of hospital attendees within the review period who were symptomatically screened for TB disaggregated by age U15 and 15+

0-14yrs	15+yrs
0/0 = 0%	0/0 = 0%

Proportion of bacteriologically diagnosed index TB patients during the review period who had their household contacts traced within one month of treatment initiation (disaggregated by age U15 and 15+).

0-14yrs	15+yrs
1 / 28 = 4%	11 / 28 = 39%

3. Proportion of presumptive TB cases identified within the review period evaluated for TB using WHO Rapid Diagnostics (Xpert MTB RIF assay, TB LAMP, LF LAM, TrueNat) or AFB microscopy.

Percentage	Value
0/0 = 0%	

4. Proportion of presumptive TB cases identified within the review period evaluated clinically (including with chest X-ray)

Percentage	Value
0/0 = 0%	

5. Proportion of presumptive TB cases identified within the review period whose sputum specimen were sent to GeneXpert Lab and had their results received within 72 hrs of sending sputum specimen to Lab

F	Percentage	Value
0	0/0 = 0%	

6. Proportion of confirmed TB cases diagnosed within the review period that have initiated treatment for TB within two days of diagnosis

Percentage	Value
0/0 = 0%	

7. Proportion of DS-TB cases with positive baseline sputum smear or Xpert MTB/RIF started on treatment in the 6 months prior to the review period with documented follow-up sputum smear AFB within the recommended time frame (2,5 & 6 months).

## Percentage Value

0/0 = 0%

8. Proportion of DS-TB patients started on treatment 6 months prior to the review period with complete documentation in the treatment card and the TB facility (treatment) register.

### Percentage Value

0/0 = 0%

#### **DRTB**

9. Proportion of patients started on second-line TB treatment during the 6 months review period who have their baseline (LPA, X-ray, AFB, HIV test, EUCr, Pregnancy test, LFT, TFT, FBS, FBC, HBV, HCV, Urinalysis, ECG) results documented after 2 weeks of sample collection.

## Percentage Value

0/0 = 0%

10. Proportion of all DR-TB cases diagnosed during the review period who initiated treatment for DR-TB within two weeks of diagnosis.

#### Percentage Value

0/0 = 0%

11. Proportion of patients started on second-line TB treatment 9 or 12 months prior to the beginning of review period (i.e. 9 or 12 months after the closing day of the cohort) who have their follow-up examinations (AFB, Culture, EUCr, ECG done monthly during the intensive phase within the review period.

### Percentage Value

0/0 = 0%

12. Proportion of DR-TB patients started on treatment 6 months prior to the review period with complete documentation in the treatment card and the DR-TB facility (treatment) register.

### Percentage Value

0/0 = 0%

#### **PAEDIATRICS**

13. Proportion of presumptive paediatric TB cases under 15 years identified within the review period who had access to either chest X-ray and/or Xpert MTB?RIF and/or stool depending

on the age

# Percentage Value

0/0 = 0%

14. Proportion of children under 15 years diagnosed with TB within the review period.

## Percentage Value

0/0 = 0%

15. Proportion of patients under 15 years among confirmed TB cases diagnosed within the review period that have initiated treatment for TB within two days of diagnosis.

### Percentage Value

0/0 = 0%

16. Proportion of paediatric TB patients started on treatment 6 months prior to the review period with complete documentation in the treatment card and the DR-TB facility (treatment) register.

# Percentage Value

0/0 = 0%

#### **FACILITY PERFORMANCE**

17. Proportion of health care workers (HCW) who were screened for TB 12 months prior to the review period.

### Percentage Value

0/0 = 0%

18. Proportion of infection control strategies in place at the facility (i.e. IPC plan and policy, IPC guidelines, IPC focal person, IPC committee [minutes of meeting], IEC materials, evidence of use of IPC checklist to monitor implementation monthly)

#### Percentage Value

0/0 = 0%